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of this regimen. However, almost all
remaining macrophages (2.7%) were
infected (92.4%), providing a potential
source of future reactivation of the
infection (Figure 2b). The vast majority
of those infected macrophages pro-
duced tumor necrosis factor-a (97.7%),
compared to non-infected F4/80-posi-
tive cells, of which only 58.4% pro-
duced tumor necrosis factor-a. Thus,
one treatment is not sufficient for the
complete eradication of L. major-in-
fected cells.
The findings from this study suggest
that the clinical outcome observed with
ALA-PDT is likely the result of unspe-
cific tissue destruction accompanied by
a depopulation of macrophages rather
than any direct killing of parasites.
Other approaches, such as those study-
ing new photosensitizers, or PDT tar-
geted specifically against Leishmania,
may also be worth exploring.
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TO THE EDITOR
Pemphigus vulgaris (PV) is the most
common variant of the human auto-
immune blistering disorders in the
pemphigus complex and accounts for
over 80% of all cases (Greenberg,
1994). Although generally considered
as disease of middle-aged adults, PV
has also been reported in children and
neonates (Bjarnason and Flosadottir,
1999). In order to rapidly institute
appropriate therapeutic measures and
thus prevent the serious morbidity that
results from extensive loss of epidermal
cohesion, it is of importance to diag-
nose PV in its very initial phase.
PV is diagnosed by virtue of its
clinical and histological presentation,
the latter being examined on routine
paraffin-embedded biopsies. Characte-
ristically PV presents with fragile blis-
ters and subsequent erosions, matched
by suprabasal cleft formation and the
presence of acantholytic cells in light
microscopy. In early stages, diagnosis
may be missed in the presence of
nonspecific, pre-bullous inflammatory
skin lesions. Upon clinical suspicion of
PV, the demonstration of intraepider-
mal IgG deposits and circulating anti-
keratinocyte membrane antibodies by
direct (DIF) and indirect (IIF) immuno-
fluorescence, respectively, was manda-
tory to prove the autoimmune origin of
the disease until recently. DIF is carried
out on native tissue from the patient as
described by Beutner and Jordon (1964)
requiring a second biopsy in case the
first biopsy was solely processed
for routine histology. A commercially
Abbreviations: BP, bullos pemphigoid; DIF and IIF, direct and indirect immunofluorescence analysis;
Dsg3, desmoglein 3; PF, pemphigus foliaceus; PV, pemphigus vulgaris; SD, seborrheic dermatitis;
TEN, toxic epidermal necrolysis
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available ELISA now allows to identify
PV more specifically than by IIF via
detection of circulating antibodies
against desmoglein (Dsg) 3, which is
the antigenic target in a large majority
of PV patients (Amagai et al., 1999a,
1999b).
We recently identified a signaling
cascade initiated by binding of PV
antibodies to Dsg3 (Williamson et al.,
2006). This cascade transiently en-
hances the turnover of plakoglobin at
the plasma membrane, a molecule that
is involved in intercellular adhesion
and signaling. This in turn results in
reduced availability of plakoglobin in
the nucleus and abrogation of its func-
tion as transcriptional repressor of the
proto-oncogene c-Myc. As a conse-
quence, c-Myc accumulates in a gen-
eralized manner in the nuclei of all
layers of skin and mucous membranes
engendering hyperproliferation. The re-
levance of c-Myc accumulation for PV
pathogenesis was demonstrated in the
previous study (Williamson et al., 2006)
by c-Myc inhibitors that prevented
pemphigus vulgaris antibodies-induced
lesion formation in the neonatal
mouse pemphigus model (Anhalt
et al., 1982). Consistently, the increase
in c-Myc is one of the earliest changes
in PV, high c-Myc levels being invari-
ably present in peri-lesional as well as
non-lesional epidermis (Williamson
et al., 2006). The importance of this
event was further underscored by the
finding that all analyzed PV patients (six
out of six human PV patients and three
out of three canine PV patients (Wil-
liamson et al., 2006, 2007) presented
with generalized high nuclear c-Myc
levels in epidermis and oral mucosa.
This raised the possibility that c-Myc
can be used as a specific marker for
early diagnosis of Dsg3 antibody-
mediated human PV even in the ab-
sence of typical histology. This was
also of particular interest because
unlike DIF, c-Myc can be investigated
on formalin-fixed paraffin-embedded
tissue (Williamson et al., 2006,
2007) which allows examination on
routine biopsies including retrospective
analyses.
Enhanced proliferation, as seen in all
PV patients analyzed (Williamson et al.,
2006, 2007), is a feature of many skin
disorders such as psoriasis or chronic
atopic dermatitis (Berardesca and
Distante, 1994; de Rie et al., 2004).
However, generalized accumulation of
c-Myc in the nucleus of keratinocytes
was ruled out in pemphigus foliaceus
(PF) and other autoimmune bullous
diseases such as bullous pemphigoid
(BP) (Williamson et al., 2006). C-Myc
expression is commonly upregulated
in tumors (Ponzielli et al., 2005), will
in the latter however not be seen in
peri-lesional and non-lesional sites as
reported for PV (Williamson et al.,
2006). These collective observations
suggested that high keratinocyte
nuclear c-Myc might be a specific
marker for PV diagnosis, requiring a
comparative in-depth survey of other
skin disorders.
Table 1. Scoring of keratinocyte nuclear c-Myc staining in various skin
disorders
Nuclear c-Myc
(n)
Peri-lesional
Ki67+(fold increase) Negative (n) Moderate (n) High (n)
PV (7)1 4–16 — — 7 G
PF (4)1 1 [11]2 4 — —
BP (4) 4–8 3 1 F —
EBA (2) 2–3 2 — —
LAD (1) 4 1 — —
Psoriasis (6) 14–21 6 — —
AD (4) 1–9 1 3 G —
SD (5) 4–12 5 — —
TEN (6) 1–12 2 4 F —
AD, atopic dermatitis; BP, bullous pemphigoid; EBA, epidermolysis bullosa acquisita; F, focal nuclear
c-Myc upregulation; G, generalized nuclear c-Myc upregulation; LAD, linear IgA disease; n, number
of different cases analyzed; PF, pemphigus foliaceus; PV, pemphigus vulgaris; SD, seborrheic
dermatitis; TEN, toxic epidermal necrolysis.
1Six of the seven PV and one of the four PF patients are shown in Williamson et al. (2006).
2Only one of four PF patients showed an increase in proliferating cells. This might be due to
regenerative proliferation.
Figure 1. High c-Myc is a molecular marker for PV. Sections of paraffin-embedded biopsies of patients
performed for clinical purposes were used according to the rules of the Medical Faculty. The diagnosis
relied on routine clinical and histological examination in autoimmune bullous diseases (PV, PF, BP,
epidermolysis bullosa acquisita, and LAD) supplemented by immunohistological (DIF) and serological
(IIF) criteria. The numbers of patients analyzed are listed in Table 1. Control biopsies were obtained from
two healthy donors. All biopsies were fixed with 4% formaldehyde, paraffin-embedded and serial
sections of the same biopsy were used for immunofluorescence analyses using antibodies to Ki67 and
c-Myc as described previously (Williamson et al., 2006). Briefly, sections were deparaffinized and
antigens retrieved by microwaving three times 5 minutes at 720 watt in 0.01 M sodium citrate buffer pH
6.0. Antibodies used were c-Myc (1:250; Upstate Biotechnology, Lake Placid, NY; #06–340) and Ki67
(1:40; Zymed, San Francisco, CA). Nuclei were counterstained with Hoechst 33258 (H-1398, Molecular
Probes, Eugene, OR). Staining was evaluated on matching biopsies and sites. One biopsy is presented
with average staining (left panels) and the one with the strongest c-Myc staining (right panels).
PF¼ pemphigus vulgaris, BP¼bullous pemphigoid, TEN¼ toxic epidermal necrolysis,
EBA¼ epidermolysis bullosa acquisita, AD¼ atopic dermatitis, SD¼ seborrheic dermatitis. Biopsies were
processed concurrently to obtain semiquantitative results. Bars¼ 200mm. Note that nuclear c-Myc levels
were highest in PV and as reported were characteristically seen in all layers of the epidermis (Williamson
et al., 2006) whereas pemphigus vulgaris antibodies were restricted to the lower part of the epidermis
(inset; PG¼plakoglobin; DIF¼direct immunofluorescence, described in (Williamson et al., 2006);
dotted line, basement membrane; discontinuous line, stratum corneum). Chosen for comparison were
two different PV patients and two different sites; the PV/PF patient described in Figure 2 (peri-lesional)
and a patient described previously (non-lesional; Williamson et al., 2006). Sections were processed
together and experimental procedures and photographic exposures held constant to obtain semiquanti-
tative results as described previously (Caldelari et al., 2001).
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Here we conducted a comparative
and retrospective analysis of biopsies
from patients with other autoimmune
bullous diseases, hyperproliferative skin
disorders as well as toxic epidermal
necrolysis (TEN), a clinically relevant
differential diagnosis of PV. Thereby,
we investigated increased proliferation
by means of Ki67-positive cells as well
as c-Myc expression by semiquantita-
tive immunofluorescence analysis. To
evaluate c-Myc in the time course of
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PV, we also performed a chronologic
study of a patient with coexisting
PV/PF, the diagnosis of which had been
delayed for more than 1 year as
characteristic acantholytic blisters were
not present in the initial biopsy (Muller
et al., 2002).
HIGH NUCLEAR C-MYC LEVELS
CHARACTERIZE PV
We used semiquantitative comparative
immunofluorescence as described pre-
viously (Caldelari et al., 2001) to retro-
spectively define c-Myc levels and
proliferation in skin biopsies from patients
with immuno/histologically diagnosed
autoimmune bullous diseases such as
PF, BP, epidermolysis bullosa acquisita,
and linear IgA disease (LAD), hyperproli-
ferative skin disorders including psoriasis,
chronic eczema (atopic dermatitis), and
seborrheic dermatitis (SD) as well as TEN.
The Ethical Committee of the University
of Bern, Medical Faculty approved all
described studies.
At the time of biopsy all the patients
with bullous disorders had active and
immunohistochemically defined disease
and none of the patients had been
treated with systemic glucocorticoster-
oids. All diseases except PF and TEN
had massively increased Ki67-positive
cells in the lesions (data not shown) and
still significant, but decreasing numbers
in peri-lesional skin (Table 1). This
pattern of increased proliferative acti-
vity towards the center of the lesion is
indicative of regenerative proliferation
secondary to the disease process. How-
ever, none of these skin disorders pre-
sented with the characteristic high levels
of nuclear c-Myc observed in lesional,
peri-lesional or even non-lesional
keratinocytes of PV patients analyzed
herein as well as in our previous study
(Figures 1 and 2, Table 1, and William-
son et al. (2006)). Some cases of BP, AD
and TEN presented with moderately
elevated levels of nuclear c-Myc
(Table 1), which, however, were clearly
distinctive in intensity of those seen in
the PV patients (Figure 1). Moreover, in
BP and TEN c-Myc was increased only
focally, and in TEN additionally often
was confined to aberrantly big nuclei in
the basal layer. Two out of six psoriatic
patients showed another particularity:
c-Myc levels were substantially in-
creased in the cytoplasm but not in the
nucleus, for currently unknown reasons.
The surprising finding that nuclear
c-Myc accumulation was not observed
in PF not only points to a different
pathomechanism in this variant of pem-
phigus, but also could be helpful in
confirming PV in case of coexisting PV/PF.
DISEASE PROGRESSION IN A
PATIENT WITH COEXISTING
PV/PF CORRELATES WITH NUCLEAR
C-MYC ACCUMULATION IN
KERATINOCYTES: A TIME COURSE
STUDY
In spring 1998, a 51-year-old man
developed itching scales and crusts on
the scalp (Muller et al., 2002). The
patient was diagnosed with impetigo-
like disease and treated with systemic
antibiotics and topical corticosteroids
without controlling development of
new lesions. Three months later, the
clinical picture resembled SD. A first
biopsy showed epidermal spongiosis
and mixed inflammatory infiltrates, but
in the lesion chosen to be analyzed,
characteristic histological signs for
pemphigus were not seen (Figure 2;
July-98 hematoxylin and eosin). Retro-
spective immunofluorescence analysis
on peri-lesional sections, however, re-
vealed high numbers of proliferating
cells (16 times more than in control
epidermis) as well as generalized and
high keratinocyte nuclear c-Myc stain-
ing (Figure 2, July-98). The distribution
pattern of c-Myc- and Ki67-positive
cells further corresponded with that
reported for other PV patients (William-
son et al., 2006 and Figure 1, top
panel). High nuclear c-Myc was seen
throughout the epidermis whereas
Ki67-positive cells, in contrast, were
mostly confined to the basal and two to
three suprabasal layers. This seemingly
discrepant localization (including that
of bound autoantibody (Figure 1, inset))
is particularly interesting as it may
relate to the diverse signaling cascades
activated downstream of cadherins and
epidermal growth factor receptors at
the transition between proliferation
and terminal differentiation (Pece and
Gutkind, 2000; Calautti et al., 2005) as
will be discussed in detail elsewhere
(Mu¨ller et al., review, unpublished).
In the months following the first
biopsy, the lesions of the scalp of our
patient spread to the face and
shoulders, only partially responding to
high potency topical glucocorticoster-
oids. Disease spreading correlated with
a moderate increase in the number of
proliferating cells and a diffuse epider-
mal cytoplasmic rather than nuclear
c-Myc staining seen by retrospective
immunofluorescence analysis of a still
histologically nonspecific biopsy from a
topically glucocorticosteroid-treated
lesion on the shoulder (Figure 2,
May-99). To perform proper diagnosis,
topical corticosteroid treatment was
suspended for 1 week. During that short
period, lesion formation exacerbated,
new lesions appearing on other parts of
the body such as the legs, which in this
case exhibited blistering with supraba-
sal and subcorneal acantholysis in
histology (Figure 2, June-99, hematox-
ylin and eosin). DIF, performed on peri-
lesional native tissue, showed granular
intercellular IgG deposits from the basal
to the granular layers and IIF on human
skin was positive with a titer of 1:512
(Muller et al., 2002). ELISA testing con-
firmed the histopathological dia-
gnosis of combined PV and PF with an
index of 192.2 for Dsg1 antibodies and
31.3 for Dsg3 antibodies (Muller et al.,
2002). Retrospective investigation of this
biopsy revealed high numbers of Ki67-
positive cells (7-fold increase) and a
substantial increase in nuclear c-Myc in
all epidermal layers (Figure 2, June-99).
Figure 2. c-Myc expression corresponds to disease activity in PV. In a patient with coexisting PV/PF (Muller et al., 2002), hematoxylin and eosin
stained sections of formalin-fixed paraffin-embedded biopsies taken over time were evaluated by routine histology to detect blister formation (left panel). Tissue
sections were examined by immunofluorescence microscopy using antibodies to Ki67 and c-Myc. Numbers indicate the increase of Ki67-positive cells in
the epidermis (counted over the entire biopsy except in the lesion) as compared to normal skin (set as 1 for the control). Glucocorticosteroid (CS) treatment
is indicated on the right. Biopsies were processed concurrently to obtain semiquantitative results. Bar¼ 200mm. Note that c-Myc levels are high during active
disease.
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Noticeably, the ELISA cutoff being 20
(Amagai et al., 1999a), the measured
Dsg3 antibody level was specific but
moderate. Despite this, typical suprabasal
blisters formed and nuclear c-Myc
was readily detectable. This indicated
that c-Myc levels represent a very
sensitive biological read out for patho-
genic activity.
Subsequently, the patient was again
treated with high potency topical corti-
costeroids. Two months later he was
finally hospitalized, presenting with
extensive erosive lesions on the scalp,
trunk, and extremities (Muller et al.,
2002). Retrospective analysis of a scalp
biopsy taken at that time revealed an
even higher number of proliferating
cells than 2 months earlier (Figure 2,
August-99). However, as already in
May-99, the more numerous Ki67-posi-
tive cells mostly localized to the basal
layer and c-Myc was present in an
unusual patchy manner with some cells
showing increased nuclear and some
increased cytoplasmic c-Myc. This sug-
gested a correlation between glucocor-
ticosteroid treatment and c-Myc
expression. After 2 weeks of immuno-
suppressive treatment with high doses of
systemic glucocorticosteroids disease
activity ceased. One year after hospita-
lization and low dose maintenance
therapy with systemic glucocorticoster-
oids for several months, biopsies
showed no skin lesions. DIF showed
discrete intraepidermal IgG deposits,
whereas IIF and ELISA were negative
(Muller et al., 2002). Retrospective
immunofluorescence analyses revealed
neither an elevation of Ki67-positive
cells nor of c-Myc staining (Figure 2,
August-00). In conclusion, in this patient
strong nuclear c-Myc expression and
concomitant hyperproliferation paral-
leled disease activity and was present
at onset of skin disorders but 1 year
before the formation of a typical PV-like
clinical and histological picture. The
fluctuations in c-Myc expression in this
patient was related to glucocorticoster-
oid treatment. This is in line with a
recent report that glucocorticosteroids
directly regulate c-Myc transcription
(Takayama et al., 2006) and further are
beneficial for keratinocyte cohesion
(Swanson and Dahl, 1983; Jeffes et al.,
1984). In addition, glucocorticosteroids
are well known for their immunomodu-
latory activity, an effect that currently
can also not be excluded.
In summary, our data suggest that
generalized and high levels of nuclear
c-Myc in peri-lesional keratinocytes
could represent a highly sensitive mar-
ker for rapid and efficient routine
diagnosis of early stage PV. This is
suggested firstly by absence of strong
nuclear c-Myc in all other skin diseases
investigated and secondly by the fol-
low-up of a PV/PF patient. Hence, if
larger series of biopsies examined in
various laboratories confirm the speci-
ficity and the sensitivity of our findings,
a novel algorithm to diagnose PV might
emerge; (I) routine histology followed
by standardized c-Myc immunofluores-
cence on a single formalin-fixed
paraffin-embedded lesional biopsy,
which when positive is further
validated by (II) quantitative Dsg3
ELISA. Based on our observations it
should however be kept in mind
that corticosteroid treatment should be
suspended for about 1 week before
taking a biopsy for c-Myc testing, or in
case of retrospective studies this
parameter has to be taken into account.
In conclusion, the procedure we
propose could not only be more con-
venient in daily dermatological practice
but will allow to diagnose PV early
on and institute appropriate therapeutic
measures that prevent the serious
consequences anti-Dsg3 PV antibodies
and the high levels of the proto-
oncogene c-Myc have for the skin
(Honeycutt and Roop, 2004; William-
son et al., 2006).
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Epidermal Deletion of Rac1 Causes Stem Cell Depletion,
Irrespective of whether Deletion Occurs during
Embryogenesis or Adulthood
Journal of Investigative Dermatology (2007) 127, 1555–1557. doi:10.1038/sj.jid.5700738; published online 15 February 2007
TO THE EDITOR
We recently reported that the Rho
GTPase Rac1 is essential for mainte-
nance of the adult epidermal stem cell
compartment (Benitah et al., 2005). We
topically applied 4-hydroxy-tamoxifen
(4OHT) to 8-week-old mice to induce
deletion of Rac1 in epidermal cells
expressing Cre recombinase fused to a
mutant estrogen receptor under the
control of the keratin 14 promoter
(K14CreER; Lo´pez-Rovira et al., 2005).
As illustrated in Figure 1a–d, the inter-
follicular epidermis underwent a well-
defined series of changes, with an
initial increase in proliferation (early
phenotype; Figure 1a, b), followed by
premature terminal differentiation (mid-
dle phenotype; Figure 1c), and then
local loss of all viable cell layers (late
phenotype; Figure 1d; Benitah et al.,
2005). In addition to the progressive
and irreversible changes in the inter-
follicular epidermis, the sebaceous
glands and hair follicles degenerated.
We showed that the changes were a
consequence of stem cell depletion, as
judged by loss of cells with several stem
cell characteristics (clonogenicity,
DNA label retention, expression of
CD34 and keratin 15). Treatment of
Rac1flox/flox or K14CreER/Rac1wt/wt con-
trol mice with 4OHT or acetone (ve-
hicle) did not produce any changes in
epidermal histology (Figure 1a and data
not shown; Benitah et al., 2005).
In contrast to our results, it has
recently been reported that deletion of
Rac1 via Cre recombinase expressed
under the control of the keratin 5
promoter (K5Cre) has no effect on the
interfollicular epidermis, even though
hair follicle integrity is compromised
(Chrostek et al., 2006). We found this
result surprising because the K5 and
K14 promoters have very similar
strengths and patterns of expression
(Byrne et al., 1994; Ramı´rez et al.
2004; Lo´pez-Rovira et al., 2005). Both
promoters are strongly upregulated by
E14.5 of embryonic development and
we would have predicted that K5Cre
deletion of Rac1 in the embryo would
have a more severe effect than deletion
in adulthood (Lo´pez-Rovira et al.,
2005).
There are certainly precedents for
gene deletion resulting in different
phenotypes in different laboratories,
and in some cases this can be ac-
counted for by differences in the
genetic background of the knock out
mice (Sibilia et al., 1998). A further
issue is the potential for artefacts arising
from the use of 4OHT-dependent Cre.
Chrostek et al. (2006) reported that
4OHT treatment caused changes in
the histological appearance of wild-
type mice. Although this has never been
our experience (Figure 1a; Frye et al.,
2003; Benitah et al., 2005; Silva-Vargas
et al., 2005), topical 4OHT can cause
changes in gene expression in wild-type
mice (Frye et al., 2003; Watt, unpub-
lished observations). K14CreER is leaky
in older mice (Vasioukhin et al., 1999;
Bleul et al., 2006) and, conversely,
4OHT treatment is not always 100%
effective at deleting the floxed gene via
CreER (Lo´pez-Rovira et al., 2005; Silva-
Vargas et al., 2005).
As the phenotype of the K14CreER/
Rac1flox/flox mice has led us to propose
that Rac1 and Myc represent a global
stem cell regulatory axis (Benitah et al.,
2005), we felt it was important to
establish whether this was true irre-
spective of the method used to express
Cre in the basal layer of the epidermis.
To determine whether the epidermal
Rac1 deletion phenotype was affected
by the chemical composition or deliv-
ery route of the Cre inducing agent, we
compared mice that had received topi-
cal applications of 4OHT (Figure 1a–d)
with mice that received intraperitoneal
injections of 5 mg of tamoxifen (Tam)
dissolved in peanut oil. Tam was
administered on days 0 and 7. Four
mice were killed at day 7, and four at
day 9. Mice could not be examined at
later time points because their health
deteriorated, as a consequence of cu-
mulative effects of deleting Rac1 in the
epidermis and internal epithelia (data
not shown). Intraperitoneal injection of
Tam caused very similar changes to
those induced by topical application of
4OHT (Figure 1e–h). The only differ-
ence was that the phenotype appeared
more rapidly, and by 7 days 6/8 mice
had developed the middle and late
phenotypes. One mouse exhibited
complete loss of all epidermal struc-
tures, including the cornified layers, in
large areas of the skin (Figure 1h).
Intraperitoneal administration of TamAbbreviations: 4OHT, 4-hydroxy-tamoxifen; Tam, tamoxifen
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